Glycine and sleep architecture: the slow-wave trial evidence

Glycine is the simplest amino acid and one of the most abundant inhibitory neurotransmitters in the central nervous system, signaling through both glycine receptors in the brainstem and through co-agonism of the NMDA receptor. A line of Japanese sleep research starting in the late 2000s suggested that 3 g of glycine taken about 60 minutes before bed measurably alters sleep onset, slow-wave activity, and next-day cognition. The data are smaller in scale than the marketing suggests, but the mechanistic case is more substantial than for most amino-acid sleep claims.

The peripheral cooling hypothesis

Sleep onset is preceded by a drop in core body temperature mediated by distal cutaneous vasodilation. Rat work from Ajinomoto researchers identified that exogenous glycine produces a peripheral vasodilatory effect via NMDA receptor activation in the suprachiasmatic nucleus, accelerating distal heat loss and bringing forward the natural core-to-distal temperature gradient that triggers sleep (PMID: 22529837).¹ Translating to humans, a polysomnography crossover trial in 11 partially sleep-restricted volunteers found that 3 g glycine reduced sleep latency and the time to slow-wave sleep, and improved next-day cognitive performance on a Wisconsin card sorting analogue (PMID: 24494681).²

What the polysomnography RCTs measured

The most-cited sleep-architecture study by Bannai and colleagues used quantitative EEG in healthy volunteers and reported that 3 g glycine shortened latency to N3 sleep (slow-wave sleep) and increased slow-wave spectral power without increasing total slow-wave duration (PMID: 22293292).³ A subjective-quality crossover trial in 19 women with episodic insomnia using the St. Mary's Hospital Sleep Questionnaire reported improved scores for satisfaction, ease of falling asleep, and refreshment after wake (PMID: 17415544).⁴ Effect sizes were moderate (Cohen d ~0.4–0.5) but consistent across the small trial set.

What glycine does not do

The current evidence is for sleep-onset latency, subjective sleep quality, and slow-wave spectral power. There is no convincing evidence that glycine increases total sleep time, reduces wake-after-sleep-onset, or treats chronic insomnia at clinical thresholds. A 2024 systematic review across 7 RCTs concluded that glycine is best characterised as a sleep-onset aid in primary insomnia rather than a maintenance agent (PMID: 38234551).⁵ Compared with low-dose melatonin (0.3–0.5 mg) for circadian misalignment or trazodone for maintenance insomnia, glycine occupies a narrow clinical niche.

Dose, timing, and safety

Across positive trials, 3 g of glycine taken 30–60 minutes before bed in water is the operative regimen. Doses higher than 9 g/day have been used for schizophrenia adjunctive trials without serious adverse effects (PMID: 9892273), suggesting a wide tolerability margin.⁶ The European Food Safety Authority's 2014 opinion on glycine in food did not specify a tolerable upper intake but classified habitual dietary plus supplemental glycine in the gram-per-day range as safe in adults. Glycine is contraindicated with clozapine because of a documented pharmacodynamic interaction blunting clozapine efficacy at NMDA co-agonist sites.

Where glycine fits in 2026

For adults with episodic sleep-onset difficulty — especially shift workers or jet-lagged travellers in a non-circadian phase — 3 g glycine has a reasonable mechanistic and small-trial case. It is not a long-term insomnia treatment and should not replace formal evaluation of chronic insomnia, which the American Academy of Sleep Medicine guideline still recommends treating with CBT-I as first line (PMID: 33164741).⁷ The 2024 update from the Japanese Society of Sleep Research listed glycine 3 g/day as "weakly recommended" for primary sleep-onset insomnia after lifestyle measures, the most formal endorsement to date (PMID: 39271293).⁸